Loading candles…
Global Health Limited is a private healthcare company operating primarily in the North and East regions of India. Founded by Dr. Naresh Trehan, the company provides multi-specialty tertiary care and complex quaternary care through a network of super-specialty hospitals. Its services span cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. Operating under the Medanta brand, Global Health Limited focuses on hospital services and has notable leadership in cardiac sciences, neurosciences, oncology, and liver transplants.
This page is a live market overview for GLOBAL HEALTH LIMITED (MEDANTA) on the NSE. As a listed security, GLOBAL HEALTH LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for MEDANTA before placing trades on tick2trade.
As of the latest feed, MEDANTA last traded at ₹1,455.6 on NSE, up ₹11.3 (0.78%) from the previous close of ₹1,444.3. Today's session range is ₹1,440.1 – ₹1,483.7, against a 52-week band of ₹956 – ₹1,483.7. Traded volume today stands at 5.51L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for MEDANTA in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether MEDANTA is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for GLOBAL HEALTH LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in MEDANTA. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated MEDANTA option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 30 Jul 2026 |
| Results - Q4 & FY26 | To consider and approve the financial results for the quarter and year ended March 31, 2026 and recommendation of final dividend, if any subject to sharehold… | 14 May 2026 |
| Results - Q3-FY25 | To consider and approve the financial results for the Third Quarter and Nine Months ended December 31, 2025. | 4 Feb 2026 |
| Unaudited Results - FY25 | To consider and approve the un-audited financial results for the period ended September 30, 2025 | 7 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 7 Aug 2025 |
| Results - Q4 & FY25 | To consider and approve the financial results for the quarter and year ended March 31, 2025 and recommend the final dividend, if any subject to shareholders … | 15 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.